SODIUM LAURYL SULFATE
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 265.0 | 3.4 | 0 | 4 | 66.0 | 12 | 1.0 |
- CAS
- 151213
- UNII
- 368GB5141J
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 57 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT02227069 | 2014-09-01 | Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers | Phase 1 | Active, Not Recruiting |
| NCT02256930 | 2014-09-01 | Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers | Phase 1 | Active, Not Recruiting |
| NCT02198963 | 2014-07-01 | 21 Day Cumulative Skin Irritation of RUT058-60 | Phase 1 | Completed |
| NCT02160574 | 2014-06-01 | Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA | Phase 1 | Completed |
| NCT02169154 | 2014-06-01 | A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel | Phase 1 | Completed |
| NCT02168478 | 2014-06-01 | Neo-Synalar Modified 48 Hour Patch Test | Phase 4 | Completed |
| NCT02117752 | 2014-04-01 | Dermal Tolerability of Dapsone Gel in Healthy Volunteers | Phase 1 | Completed |
| NCT02062073 | 2014-01-01 | Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion | Phase 1 | Completed |
| NCT02061813 | 2014-01-01 | Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion | Phase 1 | Completed |
| NCT01816529 | 2013-03-01 | Topical Safety Study of Topical Diltiazem Hydrochloride | Phase 1 | Active, Not Recruiting |
| NCT01821274 | 2013-03-01 | A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design | Phase 1 | Active, Not Recruiting |
| NCT01771822 | 2013-01-01 | Ibuprofen 5% Topical Gel CIPT | Phase 1 | Completed |
| NCT01787448 | 2013-01-01 | RIPT of Ibuprofen Topical Gel | Phase 1 | Completed |
| NCT01430312 | 2011-09-01 | 21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation | Phase 1 | Completed |
| NCT00781664 | 2008-10-01 | Cumulative Irritation Test | Phase 1 | Completed |
| NCT00680095 | 2007-01-01 | Cumulative Irritation Test | Phase 1 | Completed |
| NCT02259868 | 2005-06-01 | Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects | Phase 1 | Completed |
(Browse) Purchasable Analogs in ZINC
Functions of Sodium Lauryl Sulfate
| Af - Antifoaming (or defoaming) agent |
| Ctg - Component or coating |
| Emul - Emulsifier |
| Sani - Sanitizing agent |
| Sda - Solubilizing & dispersing agent |
Regulatory Status of Sodium Lauryl Sulfate
| Reg - Food additives for which a petition has been filed and a regulation issued. |
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Buccal | Tablet | 5.18MG |
| Buccal | Tablet, Extended Release | 5.18MG |
| Buccal/sublingual | Tablet | 1.1MG |
| Dental | Gel | 1.47% |
| Dental | Paste | |
| Oral | Capsule | 21.6MG |
| Oral | Capsule (Immed./comp. Release), Hard Gelatin | 3.6MG |
| Oral | Capsule, Delayed Action | 2MG |
| Oral | Capsule, Delayed Action, Coated, Hard Gelatin | 2MG |
| Oral | Capsule, Delayed Action, Enteric Coated | |
| Oral | Capsule, Delayed Release | 1MG |
| Oral | Capsule, Enteric Coated Pellets | 0.6MG |
| Oral | Capsule, Extended Release | 16.67MG |
| Oral | Capsule, Hard Gelatin | 7MG |
| Oral | Capsule, Soft Gelatin | 96MG |
| Oral | Capsule, Sustained Action | 9.47MG |
| Oral | Capsule, Sustained Action, Hard Gelatin | 1.7MG |
| Oral | Dispersible Tablet | 8.4MG |
| Oral | Drops | |
| Oral | Granule | |
| Oral | Powder, For Inhalation | |
| Oral | Powder, For Suspension | 0.07% |
| Oral | Suspension | 0.15% |
| Oral | Tablet | 51.69MG |
| Oral | Tablet (Immed./comp. Release), Coated | 1MG |
| Oral | Tablet (Immed./comp. Release), Film Coated | 0.98MG |
| Oral | Tablet (Immed./comp. Release), Uncoated, Chewable | 5MG |
| Oral | Tablet, Coated | 5.2MG |
| Oral | Tablet, Delayed Action | 1.64MG |
| Oral | Tablet, Delayed Action, Enteric Coated | 8.09MG |
| Oral | Tablet, Delayed Release | 0.0002MG |
| Oral | Tablet, Extended Release | 51.69MG |
| Oral | Tablet, Film Coated | 12MG |
| Oral | Tablet, Multilayer, Extended Release | 0.8MG |
| Oral | Tablet, Orally Disintegrating | 2MG |
| Oral | Tablet, Sustained Action | 20.62MG |
| Oral | Tablet, Sustained Action, Coated | 10.5MG |
| Oral-28 | Tablet | 0.65MG |
| Sublingual | Tablet | 0.02MG |
| Topical | Emulsion, Cream | 2.5% |
| Topical | Lotion | 0.5% |
| Topical | Ointment | 1% |
| Topical | Shampoo | |
| Topical | Shampoo, Suspension | 40%W/V |
| Topical | Sponge | |
| Vaginal | Cream, Emulsion, Sustained Release | 0.3% |
| Vaginal | Emulsion, Cream | 0.33% |
| Vaginal | Insert | 5MG |
| Vaginal | Tablet | 5MG |